阿奇霉素序贯疗法合用布地奈德氧气雾化吸入在小儿支原体肺炎治疗中的应用  

Application of Azithromycin Sequential Therapy Combined with Budesonide Oxygen Aerosol Inhalation in the Treatment of Children with My⁃coplasma Pneumonia

作　　者：陈炜[1] 马泽南 邹公民[1] CHEN Wei;MA Ze'nan;ZOU Gongmin(Department of Pediatrics,Suzhou Wuzhong People's Hospital,Suzhou,Jiangsu Province,215000 China)

机构地区：[1]苏州市吴中人民医院儿科,江苏苏州215000

出　　处：《中外医疗》2022年第33期1-4,共4页China & Foreign Medical Treatment

基　　金：2019年度苏州市科技发展计划(民生科技-医疗卫生应用基础研究)(SYSD2019051)。

摘　　要：目的探讨对小儿支原体肺炎以阿奇霉素联合雾化吸入布地奈德干预的效果。方法随机选取2018年1月-2021年12月苏州市吴中人民医院收治的支原体肺炎患儿80例为研究对象,以随机数表法分为对照组(n=40,采用阿奇霉素序贯疗法治疗)和观察组(n=40,在对照组基础上联合布地奈德氧驱雾化吸入治疗),对比两组临床疗效,治疗后患儿典型症状改善时间,治疗前后降钙素原(PCT)、肿瘤坏死因子(TNF-α)、白介素-8(IL-8)水平及不良反应发生率。结果观察组总有效率较对照组高(95.00%vs 77.50%),差异有统计学意义(χ^(2)=5.165,P<0.05)。观察组日间咳嗽、夜间咳嗽、发热、肺啰音消失时间分别为(4.74±1.25)、(5.52±1.31)、(3.35±1.17)、(7.15±2.35)d,均短于对照组,差异有统计学意义(t=5.778、9.097、4.471、3.110,P<0.05)。治疗后观察组PCT、TNF-α、IL-8水平分别为(2.52±0.86)μg/L、(16.29±2.40)ng/L、(4.15±1.28)ng/L,均低于对照组,差异有统计学意义(t=10.112、8.804、11.536,P<0.05)。两组不良反应发生率(10.00%vs 5.00%)比较,差异无统计学意义(χ^(2)=0.180,P>0.05)。结论针对小儿支原体肺炎在阿奇霉素治疗基础上,通过雾化吸入布地奈德干预,能提高疗效,可促进肺炎症状改善,并能改善机体炎症反应,且用药安全可靠。Objective To investigate the effect of azithromycin combined with budesonide inhalation in children with mycoplasma pneumonia.Methods 80 children with mycoplasma pneumonia admitted to Wuzhong People's Hospital of Suzhou City from January 2018 to December 2021 were randomly selected as the study objects,and divide them into control group(n=40,with azithromycin sequential therapy),and observation group(n=40,with budesonide oxygen spray inhalation on the basis of control group),according to the random number table.Compared the clinical efficacy,the improvement time of the children's typical symptoms after treatment,the procalcitonin(PCT),tumor necrosis factor(TNF-α)interleukin-8(IL-8)level before and after treatment,incidence of adverse reactions of the two groups.Results The total effective rate of the observation group was higher than that of the control group(95.00%vs 77.50%),and the difference was statistically significant(χ^(2)=5.165,P<0.05).In the observation group,the disappearance time of daytime cough,night cough,fever and lung rales were(4.74±1.25)d,(5.52±1.31)d,(3.35±1.17)d and(7.15±2.35)d,respectively,shorter than those of the control group,and the difference was statistically significant(t=5.778,9.097,4.471,3.110,P<0.05).After treatment,the levels of PCT,TNF-αand IL-8 in the observation group were(2.52±0.86)μg/L,(16.29±2.40)ng/L and(4.15±1.28)ng/L,respectively,all lower than those of the control group,and the difference was statistically significant(t=10.112,8.804,11.536,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(10.00%vs 5.00%)(χ^(2)=0.180,P>0.05).Conclusion On the basis of azithromycin treatment for mycoplasma pneumonia in children,intervention by oxygen aerosol inhalation of budesonide can improve the curative effect,can promote the improvement of pneumonia symptoms,and can improve the body inflammatory response,and the drug is safe and reliable.

关 键 词：小儿支原体肺炎 阿奇霉素 序贯疗法 布地奈德 氧驱雾化吸入 不良反应 

分 类 号：R4[医药卫生—临床医学]